Silodosin filed for Chinese approval
This article was originally published in Scrip
Daiichi Sankyohas submitted an approval application to China's State FDA for the alpha 1a-adrenoceptor antagonist silodosin, for the treatment of dysuria associated with benign prostatic hyperplasia. The oral product is licensed from originatorKissei, with which Daiichi Sankyo co-markets it in Japan as Urief. Licensee Recordati filed for EU approval in November and Watson Pharmaceuticals received marketing clearance (as Rapaflo) in the US, Canada and Mexico in the previous month.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.